Sickle Cell Disease |
1 Department of Hematology, Academic Medical Centre, Amsterdam, The Netherlands;
2 Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands;
3 Immunology Department, Red Cross Blood Bank Foundation, Curaçao, Netherlands Antilles;
4 Department of Hematology, Erasmus Medical Centre, Rotterdam, The Netherlands
Correspondence: Bart J. Biemond, MD, PhD, Department of Haematology, F4-224, Academic Medical Centre, PO box 22660 1100 DD Amsterdam, The Netherlands. Phone: international +31.20.5665785. Fax: international +31.20.6919743 E-mail: b.j.biemond{at}amc.uva.nl
The glycocalyx is an important anti-inflammatory and anti-adhesive barrier at the luminal side of endothelial cells. Glycocalyx volume was significantly reduced in sickle cell patients (HbSS/HbSβ0–tha-lassemia median 0.47L, IQR 0.27–0.66, HbSC/HbSβ+-thalassemia 0.23L, 0.0–0.58) compared with controls (1x109L, 0.52–1.77) (p=0.03). Reduced glycocalyx may be a new factor in the pathophysiology of sickle cell disease.
This article has been cited by other articles:
![]() |
J. J.C. Kroot, C. M.M. Laarakkers, E. H.J.M. Kemna, B. J. Biemond, and D. W. Swinkels Regulation of serum hepcidin levels in sickle cell disease Haematologica, June 1, 2009; 94(6): 885 - 887. [Full Text] [PDF] |
||||